常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.56/-0.75
|
|
企业价值
325.19M
|
| 资产负债 |
|
每股账面净值
-7.12
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
76.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/19 12:33 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment.Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease. |

2.265 
